Benzinga · Feb 3, 2026
AD
NASDAQ · ADXN
Addex Therapeutics Ltd
Healthcare · Biotechnology
$3.39
Down-$0.22 (-6.09%)
Updated Sep 11, 2026, 7:59 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.81M
- P/E ratio
- -0.89
- Dividend yield
- 0.00%
- 52-week range
- $3.40 – $7.60
- Volume
- 14.17K
- Avg. volume
- 6.27K
Price performance
ADXN price history
1M range · 16 trading sessions · Daily adjusted prices
ADXN closed at $3.39 after 16 trading sessions, down 40.53% for the selected period.
- Last close
- $3.39
- Period change
- -40.53%
- Period low
- $3.39
- Period high
- $5.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $3.67 | $3.80 | $3.39 | $3.39 | 14.17K |
| Sep 9, 2026 | $3.67 | $3.7899 | $3.55 | $3.61 | 49.86K |
| Sep 8, 2026 | $3.65 | $3.84 | $3.53 | $3.70 | 60.15K |
| Sep 4, 2026 | $3.69 | $3.91 | $3.62 | $3.65 | 133.98K |
| Sep 3, 2026 | $3.66 | $3.91 | $3.43 | $3.71 | 174.01K |
| Sep 2, 2026 | $3.75 | $3.80 | $3.40 | $3.52 | 23.43K |
| Sep 1, 2026 | $3.86 | $3.87 | $3.6295 | $3.65 | 22.89K |
| Aug 31, 2026 | $3.91 | $3.97 | $3.71 | $3.92 | 16.24K |
| Aug 28, 2026 | $3.97 | $4.065 | $3.83 | $3.84 | 21.66K |
| Aug 27, 2026 | $4.20 | $4.275 | $3.85 | $3.85 | 37.98K |
| Aug 26, 2026 | $4.43 | $4.43 | $3.86 | $4.23 | 97.93K |
| Aug 25, 2026 | $4.05 | $4.1896 | $3.73 | $3.90 | 76.77K |
| Aug 24, 2026 | $4.59 | $4.59 | $3.76 | $4.05 | 200.89K |
| Aug 21, 2026 | $5.87 | $6.05 | $4.60 | $4.94 | 7.27M |
| Aug 20, 2026 | $5.87 | $6.205 | $3.78 | $4.57 | 248.15K |
| Aug 17, 2026 | $5.70 | $5.70 | $5.70 | $5.70 | 406 |
Latest ADXN news
The latest Smart Investors Daily articles mentioning ADXN.
Stock researchCompany · Overview
ADXN research
Overview
Company profile and research snapshot.
Company profile
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 6, 2024 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Jun 5, 2024 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Nov 29, 2023 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Nov 28, 2023 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Aug 10, 2023 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Dec 4, 2025
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call December 4, 2025 10:00 AM ESTCompany ParticipantsTimothy Dyer - Co-Founder, CEO & DirectorMikhail...
seekingalpha.com · Dec 4, 2025
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
